Skip to main content

Achieve Life Sciences Inc(ACHV-Q)

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation

Globe Newswire - Tue Jan 4, 2022

SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the last study follow-up visit for the last subject enrolled in the ORCA-2 Phase 3 trial occurred in late December 2021.


Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.